Why Acadia Pharma Shares Are Falling Today

  • Acadia Pharmaceuticals Inc ACAD announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. 
  • The primary endpoint, a comparison of cumulative pain intensity scores over 24 hours between the ACP-044 1600 mg once daily, ACP-044 400 mg four times daily, and placebo treatment arms, was not met.
  • A trend favoring the ACP-044 400 mg once every six hours treatment group was observed on the primary endpoint, a difference of -10.5 points compared to placebo (p = 0.1683; effect size = 0.219). 
  • These numerical trends were consistently better than placebo but not statistically significant at 48 hours and 72 hours.
  • Read Next: Acadia Resubmits Pimavanserin US Application For Expanded Use In Alzheimer's Psychosis.
  • "We are disappointed that the ACP-044 bunionectomy study did not meet its primary endpoint, especially given the significant need for novel, non-opioid treatment options for postsurgical pain," said CEO Steve Davis.
  • Most adverse events were mild-to-moderate, and there were no serious adverse events related to ACP-044. 
  • Acadia is currently evaluating ACP-044 in an ongoing study in osteoarthritis, a model of chronic pain, which is expected to complete in the first half of 2023.
  • ACP-044 is a non-opioid, redox modulator investigational drug in development to treat acute and chronic pain.
  • Price Action: ACAD shares are down 7.72% at $20.68 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsPhase 2 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!